

RESEARCH ARTICLE

Open Access

Exploring the metabolic network of the epidemic pathogen *Burkholderia cenocepacia* J2315 via genome-scale reconstruction

Kechi Fang^{1†}, Hansheng Zhao^{1,2†}, Changyue Sun¹, Carolyn M C Lam³, Suhua Chang^{1,4}, Kunlin Zhang¹, Gurudutta Panda³, Miguel Godinho^{3,5}, Vitor A P Martins dos Santos^{3,6*} and Jing Wang^{1*}

Abstract

Background: *Burkholderia cenocepacia* is a threatening nosocomial epidemic pathogen in patients with cystic fibrosis (CF) or a compromised immune system. Its high level of antibiotic resistance is an increasing concern in treatments against its infection. Strain *B. cenocepacia* J2315 is the most infectious isolate from CF patients. There is a strong demand to reconstruct a genome-scale metabolic network of *B. cenocepacia* J2315 to systematically analyze its metabolic capabilities and its virulence traits, and to search for potential clinical therapy targets.

Results: We reconstructed the genome-scale metabolic network of *B. cenocepacia* J2315. An iterative reconstruction process led to the establishment of a robust model, *i*KF1028, which accounts for 1,028 genes, 859 internal reactions, and 834 metabolites. The model *i*KF1028 captures important metabolic capabilities of *B. cenocepacia* J2315 with a particular focus on the biosyntheses of key metabolic virulence factors to assist in understanding the mechanism of disease infection and identifying potential drug targets. The model was tested through BIOLOG assays. Based on the model, the genome annotation of *B. cenocepacia* J2315 was refined and 24 genes were properly re-annotated. Gene and enzyme essentiality were analyzed to provide further insights into the genome function and architecture. A total of 45 essential enzymes were identified as potential therapeutic targets.

Conclusions: As the first genome-scale metabolic network of *B. cenocepacia* J2315, *i*KF1028 allows a systematic study of the metabolic properties of *B. cenocepacia* and its key metabolic virulence factors affecting the CF community. The model can be used as a discovery tool to design novel drugs against diseases caused by this notorious pathogen.

Background

Burkholderia cenocepacia is a Gram-negative opportunistic pathogen and formerly Genomovar III of *Burkholderia cepacia* complex (Bcc). The Bcc comprises at least 17 taxonomically related species [1-3], which have developed diverse niches from the natural environment [4] and humans as they have emerged as pathogens in patients with cystic fibrosis (CF), chronic granulomatous disease, and in immunocompromised individuals [5]. *B. cenocepacia* is the dominant Bcc species in patients with CF, accounting for between 50% and 80% of the infection cases [5]. It also causes many instances of non-CF clinical

infections, such as for cancer patients [6,7]. As a representative isolate for the spread of an epidemic CF strain, *B. cenocepacia* J2315 belongs to a clonal lineage known as ET12, which is of increased transmissibility and dominates fatal infections among CF patients in the United Kingdom and Canada [8-12]. *B. cenocepacia* J2315 is notorious for its high resistance to the majority of clinically useful antimicrobial agents [6,13], including antimicrobial peptides [14,15]. Yet the mechanisms of host infection and drug resistance remain mostly unknown.

The genome of *B. cenocepacia* J2315 has been sequenced and recently annotated [13]. It is one of the largest Gram-negative genomes consisting of three circular chromosomes with 3.8, 3.2 and 0.8 million base pairs (Mb) respectively and a plasmid. Its complex genome encodes a broad range of metabolic capabilities,

* Correspondence: vitor.martinsdosantos@wur.nl; wangjing@psych.ac.cn

† Contributed equally

Full list of author information is available at the end of the article

and numerous virulence and drug resistance functions that allow it to survive under a variety of conditions and invade immunocompromised individuals. It is vital to develop a systems-level metabolic model for this opportunistic human pathogen to explore and gain insights into its versatile metabolic capability and disease-causing mechanism, and eventually aid in finding potential clinical therapeutic targets. The genome-scale metabolic reconstruction enables integration of genomic information with metabolic activities observed in phenotypic experiments and other “omics” measurements to elicit hidden biological knowledge that would have been otherwise difficult to obtain.

In this study, we presented the manually curated genome-scale metabolic network of *B. cenocepacia* J2315, named as *iKF1028*, which accounts for the major metabolic pathways for the synthesis of each component of biomass and for the degradation of common biologically important carbon sources. Syntheses pathways for key virulence factors highly associated with metabolism were particularly emphasized and reconstructed. The *in silico* model was validated by performing BIOLOG substrate utilization assays, which can test the ability of a microorganism to oxidize various substrates simultaneously [16]. Model-driven analysis and discoveries, including refinement of gene annotation, and gene and enzyme essentiality, were carried out to define the architecture of the genome-wide metabolic and transport network and assist the identification of potential drug targets. Model *iKF1028* provides researchers a framework to explore and understand the global metabolism of *B. cenocepacia* J2315 and its key metabolic virulence factors affecting CF patients upon infection. It allows a broad spectrum of basic and practical applications, especially the application for drug design which may open new doors for anti-infection strategies.

Results and discussion

Characteristics of the genome-scale metabolic network of *B. cenocepacia* J2315

The genome-scale reconstructed metabolic model of *B. cenocepacia* J2315, referred by the conventional naming

rules [17] as *iKF1028*, consists of 859 internal reactions (including transport) and 834 metabolites. The reconstruction accounts for 1,028 genes, covering 14.4% of the 7,116 protein coding genes identified from whole genome sequencing (<http://www.ncbi.nlm.nih.gov/genome?term=burkholderia%20cenocepacia%20J2315>). The model *iKF1028* includes all major pathways required for cell growth and the degradation of common biologically important carbon sources of *B. cenocepacia*. Apart from these central metabolic pathways, model *iKF1028* also includes pathways associated with key metabolic virulence factors, which provides insights into how the system-level metabolic properties affect pathogenicity. For an overview, the properties of the J2315 genome and the reconstructed model *iKF1028* were summarized in Table 1. Genome-scale metabolic models have been successfully used to study many pathogenic bacteria, including *Staphylococcus aureus* [18-20], *Acinetobacter baumannii* [21], *Mycobacterium tuberculosis* [22], *Salmonella typhimurium* [23], and *Pseudomonas aeruginosa* [24]. A basic comparison between the model *iKF1028* and the above five recently published metabolic reconstructions is also illustrated in Table 1. Schematic representation of the metabolic network of *B. cenocepacia* J2315 with key metabolic virulence factors is shown in Figure 1. Figure 2 enumerates the metabolic pathways included in *iKF1028* and, for each pathway, the number of reactions with assigned and non-assigned genes. The high ratio of gene-associated reactions shows that the reconstructed metabolic model of *B. cenocepacia* J2315 is reliable. [Additional file 1 for *iKF1028* and Additional file 2 is in SBML format]

Metabolic virulence factors in model *iKF1028*

The success of *B. cenocepacia* as a pathogen originates from the ability of its large genome to encode numerous virulence mechanisms [13], including quorum sensing (QS) [25-30], siderophores-based iron uptake systems [31-33], cable pili and adhesion [34-36], motility [37,38], hemolysin [39], ZmpA and ZmpB proteases [40-42], phospholipases [43], secretion systems [44-46], lipopolysaccharides (LPS)

Table 1 Comparison of properties of reconstructed metabolic network for selected pathogens

Model	N.A.*	AbyMBEL891	iNJ661	iRR1083	iMO1056	iKF1028
Genome size	2.8 Mb	3.93 Mb	4.4 Mb	4.8 Mb	6.3 Mb	8.1 Mb
Included genes	758	650	661	1,083	1,056	1,028
Total reactions	1,497	891	939	1,087	883	859
Gene-associated reactions (% of total reactions)	1,278	713 (80%)	723 (77%)	1,018 (93.7%)	839 (95%)	832 (96.9%)
Non-gene-associated reactions	219	46	216	69	44	27
Transport reactions	146	130	93	230	133	102
Metabolites	1,431	778	828	744	760	834

Properties of metabolic reconstruction of *B. cenocepacia* J2315 (*iKF1028*) were compared with other published metabolic reconstructions of pathogenic microbes, *S. aureus* N315 (2009) [18] (which is the improvement of the N315 reconstruction by Becker and Pálsson 2005 [19], and Heinemann et al. 2005 [20]), *A. baumannii* AYE (AbyMBEL891) (2010) [21], *M. tuberculosis* H37Rv (iNJ661) (2007) [22], *S. typhimurium* LT2 (iRR1083) (2009) [23], and *P. aeruginosa* PAO1 (iMO1056) (2008) [24]. *: Not available for the reconstruction of *S. aureus* N315.




Figure 1 Schematic representation of the metabolic network in *B. cenocepacia* J2315, referred as model iKF1028.

[15,47-49], and extracellular capsule [50]. Syntheses of the key metabolic virulence factors of these virulent mechanisms, namely QS, LPS and rhamnolipids, were incorporated and analyzed in iKF1028. Table 2 lists the virulence-associated pathways and the required proteins and precursors for syntheses of virulence factors in each pathway.

The LPS produced by *B. cenocepacia* J2315 has an important role in both disease aetiology and antibiotic resistance [51,52]. LPS usually consists of three components: lipid A, core oligosaccharide, and O antigen. Although there were some studies on characterizing the

features of LPS in *B. cenocepacia*, all these studies focused on a certain part/component of LPS. So far, there is no systematic elucidation of the LPS structure and composition specifically for *B. cenocepacia* strain J2315, nor any global analysis on its biosynthesis process of the LPS. In this study, we depicted the detailed features of the complete LPS structure in *B. cenocepacia* J2315 by integrating all available reports on LPS. We also reconstructed the LPS-synthesis pathways supplemented with all necessary proteins involved and major metabolic precursors, as illustrated in Figure 3. According to our study, in J2315, each of the three components has a very unique feature. The lipid A portion is modified by an additional Ara4N residue [49,53], which had been shown to reduce the binding of cationic antibiotics and was proposed as a potential drug target [54]. The inner core oligosaccharide contains an unusual KDO-KO-Ara4N residue instead of the typical KDO-KDO residue [15,51,55]. The outer core comprises various polysaccharides including L-glycero-D-mannoheptose, glucose, galactose, quinovosamine, and rhamnose [51]. The O-antigen portion of LPS in J2315 was interrupted by an insertion element in BCAL3125 [47,56]. These differences might indicate the reason why strain J2315 is of remarkably distinct activity.

B. cenocepacia strains possess multiple quorum sensing systems, which regulate the expression of versatile




Figure 2 Metabolic pathways included in iKF1028 and the distribution of gene-associated and non-gene-associated reactions for each pathway.

Table 2 Virulence factors incorporated in the metabolic network reconstruction of *B. cenocepacia* J2315

Virulence factors	Proteins involved	Major metabolic precursors
<i>Lipopolysaccharide components</i>		
Lipid A	LpxA, LpxB, LpxC, LpxD, LpxH, LpxK, KdsA, KdsB, KdsC, KdtA, KdoO, HtrB	O ₂ , UDP-N-acetyl-D-glucosamine, (R)-3-Hydroxytetradecanoyl-ACP, (R)-3-Hydroxyhexadecanoyl-ACP, Myristoyl-ACP, D-arabinose 5-phosphate, Phosphoenolpyruvate,
Core oligosaccharide	GmhA, RfaE, GmhB, HldD, RmlD, Wbil, WaaC, WaaF, WabP, WabR, WabO, WabS, WaaL	Sedoheptulose 7-phosphate, UDP-glucose, UDP-N-acetyl-D-glucosamine, dTDP-4-dehydro-6-deoxy-L-mannose, L-Alanine
Ara4N modification	ArnA1, ArnA2, ArnB, ArnC, ArnT	L-Glutamate, 10-Formyltetrahydrofolate, UDPGlucuronate
<i>Quorum sensing</i>		
AHLs	CepI, CciI	S-adenosyl-L-methionine, Octanoyl-ACP, Hexanoyl-ACP
HHQ	KynA, KynB, KynU, PqsA, PqsB, PqsC, PqsD	L-Tryptophan, 3-oxodecanoyl-ACP
BDSF	RpfF, FadA, FadB, FadH	(S)-Hydroxydecanoyl-CoA
<i>Rhamnolipids</i>	RhlA, RhlB, RhlC, PhaC	dTDP-4-dehydro-6-deoxy-L-mannose, (R)-3-Hydroxydecanoyl-ACP

Ara4N, 4-amino-4-deoxy-arabinose; AHLs, N-acylhomoserine lactones; HHQ, 2-heptyl-4-quinolone; BDSF, *cis*-2-dodecenoic acid

virulence determinants, such as biofilm formation and motility. Strain J2315 owns the ability to synthesize and recognize three types of chemical signals used for cell-to-cell communication: *N*-acylhomoserine lactones (AHLs), 4-quinolones (4Qs), and the DSF-like molecule *cis*-2-dodecenoic acid (BDSF). Two AHLs-based QS systems have been found in J2315, namely CciIR and CepIR [25,57], which can both produce *N*-hexanoyl-L-homoserine lactone (C6-HSL) and *N*-octanoyl-L-homoserine lactone (C8-HSL) signals using acyl side chain (Hexanoyl-ACP and Octanoyl-ACP, respectively) and *S*-adenosyl-methionine (SAM) as precursors [58]. The CepIR system is conserved in all species of the Bcc. The CciIR system is encoded within a pathogenicity island, designated as the *B. cenocepacia* island (cci), which was the first time that cell-signalling genes were found on a genomic island [59]. The 4Qs-based signal, the 2-heptyl-4-quinolone (HHQ), is produced by *B. cenocepacia* strains [26]. HHQ is the precursor of 2-heptyl-3-hydroxy-4-quinolone (PQS) [60] and its synthesis requires four proteins: PqsA, PqsB, PqsC, and PqsD. It had been reported that the exported HHQ from *B. cenocepacia* can be recognized by *Pseudomonas aeruginosa* within which HHQ is converted into PQS which is one of the QS signals for *P. aeruginosa* [26], highlighting the possibility of inter-species communication during the

CF co-infection caused by *P. aeruginosa* and *B. cenocepacia*. BDSF is a newly discovered signal molecule produced by *B. cenocepacia* [28]. The synthesis of BDSF requires the gene BCAM0581 [29].

The synthesis pathway of rhamnolipids was also reconstructed in iKF1028. Although there has not been any report demonstrating that *B. cenocepacia* can produce rhamnolipid, Dubeau *et al* demonstrated that *Burkholderia thailandensis* has the orthologs of rhlA, rhlB, and rhlC, which are responsible for the biosynthesis of rhamnolipids in *P. aeruginosa* [61]. By protein similarity search against the UniProt database, proteins coded by genes BCAM2340, BCAM2338, and BCAM2336 in *B. cenocepacia* J2315 were identified as highly similar in sequence to rhlA, rhlB, and rhlC in both *B. thailandensis* (with BLAST E value of 1E-121, 1E-173, and 1E-108, respectively) and *P. aeruginosa* (with BLAST E value of 3E-60, 7E-98, and 1E-67, respectively). This facilitates us to hypothesize that *B. cenocepacia* can potentially generate rhamnolipids. Further experimental investigations are needed.

Model validation and gap-filling using phenotype data
 BIOLOG substrates utilization assays for *B. cenocepacia* J2315 were performed in triplicates in order to validate and refine the model. *In silico* growth on various




Figure 3 Specific structure of Lipopolysaccharide (LPS) in *B. cenocepacia* J2315 and the synthesis pathways of LPS as well as the proteins involved. The lipid A portion of LPS is composed of two linked glucosamine residues (purple hexagon) with fatty acid side chains (wavy lines), (*R*)-3-hydroxyhexadecanoic (C16:0 (3-OH)) in an amide linkage and (*R*)-3-hydroxytetradecanoic (C14:0 (3-OH)) acid and tetradecanoic acid (C14:0) in an ester linkage. There are 4-amino-4-deoxyarabinose (Ara4N, brown sphere) moieties attached to the phosphate residues in the lipid A backbone. The inner core oligosaccharide contains unusual KDO-KO-Ara4N residue linked to the lipid A (KDO: 3-deoxy-D-manno-octulosonic acid, dark blue hexagon; KO: D-glycero-D-talo-octulosonic acid, light blue hexagon). Various polysaccharides comprise the outer core oligosaccharide (L-glycero-D-manno-heptose, blue heptagon; glucose, dark green hexagon; galactose, light green hexagon; quinovosamine, orange hexagon; rhamnose, red hexagon). J2315 cannot make complete LPS O-antigen, owing to an insertion element in BCAL3125 [47].

substrates was simulated by setting each of them as sole carbon source and its uptake rate to 10 mmol/g_{cell}/h under aerobic conditions based on M9 minimal medium. The simulation was performed on the ToBiN platform by flux balance analysis, as described in Methods.

Of the 95 carbon sources tested, 40 could be directly compared with the *in silico* model of *B. cenocepacia* J2315, iKF1028. Preliminary disagreement between BIO-LOG assays and *in silico* predictions were probably due to metabolic gaps, improper gene annotations and

unacquainted transporters. These discrepancies were checked through gap analysis and literature mining. After continuous gap-filling and network refinement, the overall prediction accuracy was improved to 87.5%, a value that supported *iKF1028* as being a proper reconstruction of the *B. cenocepacia* J2315 core metabolism (comparison results are showed in Table 3).

Of the remaining 55 carbon sources tested, 14 were indirectly compared with the model due to the missing knowledge of whether the transport mechanisms of

these compounds exist in J2315 or not. Initially, all those 14 carbon sources showed a no-growth phenotype both *in silico* and in the BIOLOG assays. Then we made the assumption that each of these carbon sources could be transported into the cell (*i.e.* to function as intracellular compounds) and re-tested whether the *in silico* model can grow on each of them. The results showed that 11 of the 14 carbon sources enabled *iKF1028* to grow after applying the above assumption. This supports the hypothesis that J2315 lacks of transporters for all

Table 3 Comparison with the BIOLOG substrates utilization assays

Class	Carbon source	BIOLOG results	<i>In silico</i> prediction	Agreement
Carbohydrates	<i>N</i> -Acetyl-D-glucosamine	No Growth	No Growth	yes
	D-Galactose	Growth	Growth	yes
	α -D-Glucose	Growth	Growth	yes
	<i>m</i> -Inositol	No Growth	No Growth	yes
	Sucrose	Growth	Growth	yes
	D-Trehalose	Growth	Growth	yes
Carboxylic acids	Acetic acid	Growth	Growth	yes
	<i>cis</i> -Aconitic acid	Growth	Growth	yes
	Citric acid	Growth	Growth	yes
	D-Gluconic acid	Growth	Growth	yes
	β -Hydroxybutyric acid	Growth	Growth	yes
	α -Ketoglutaric acid	Growth	Growth	yes
	D,L-Lactic acid	Growth	Growth	yes
	Malonic acid	Growth	Growth	yes
	Propionic acid	No Growth	No Growth	yes
	Quinic acid	Growth	Growth	yes
	D-Saccharic acid	Growth	Growth	yes
	Succinic acid	Growth	Growth	yes
	Amino acids	L-Alanine	Growth	Growth
L-Asparagine		Growth	Growth	yes
L-Aspartic acid		No Growth	Growth	no
L-Glutamic acid		Growth	Growth	yes
L-Histidine		Growth	Growth	yes
Hydroxy-L-proline		Growth	Growth	yes
L-Leucine		No Growth	Growth	no
L-Ornithine		No Growth	Growth	no
L-Phenylalanine		Growth	Growth	yes
L-Proline		Growth	Growth	yes
L-Pyroglutamic Acid		Growth	Growth	yes
L-Serine		Growth	Growth	yes
L-Threonine		No Growth	Growth	no
D,L-Carnitine		No Growth	No Growth	yes
γ -Aminobutyric acid		Growth	Growth	yes
Miscellaneous	Succinamic acid	Growth	Growth	yes
	Uridine	No Growth	No Growth	yes
	Thymidine	No Growth	No Growth	yes
	Putrescine	No Growth	No Growth	yes
	2,3-Butanediol	No Growth	No Growth	yes
	Glycerol	No Growth	Growth	no
	D-Glucose-6-Phosphate	Growth	Growth	yes

those 11 carbon sources, even though their catabolic pathways are complete. For the rest 3 carbon sources, the agreement between the *in silico* results and BIOLOG assays remained.

As the catabolism of the remaining 41 carbon sources out of 55 has not been well studied and information regarding their role in the cell could not be found in public resources, these 41 carbon sources cannot be analyzed in our model. (Complete comparison results with BIOLOG assays are supplied in the Additional file 3).

Model-driven refinement of genome annotation

The reconstruction of metabolic network allowed the identification and refinement of improperly annotated genes of *B. cenocepacia* J2315 from the public biological databases. Careful effort was made in this work to rectify the current genome annotation based on metabolic gap analysis, BLAST searches, BIOLOG substrate utilization assays, and literature mining. The full list of refinement of genome annotation derived from the genome-scale metabolic reconstruction is shown in Table 4.

The first type of refinement was to re-annotate genes in *iKF1028* - based on literature evidence and BLAST searches - that have been improperly annotated. An example is the gene BCAL1281, which was annotated in both the *Burkholderia* Genome Database and KEGG as a "hypothetical protein", but that was now reassigned coding for an "ornithine *N*-acyltransferase". It was reported that the outer membrane of "*B. cepacia*" [62] possesses unusual polar lipids, ornithine amide lipids (OL) [63,64]. In addition, the protein OlsB is required for the first step of OL biosynthesis [65]. By BLAST searches of OlsB against the UNIPROT database, the gene BCAL1281 of *B. cenocepacia* J2315 was identified with high similarity.

Another type of annotation refinement was based on gap analyses, which pinpointed reactions for which the gene products involved were missing. For instance, we identified a missing reaction that should be catalyzed by IspE and that takes part in the biosynthesis of polyprenyl-PP, a necessary precursor of the ubiquinone biosynthesis. The IspE encoding genes for other strains of *B. cenocepacia* (AU1054, HI2424, MC0-3) could be identified in the *Burkholderia* Genome Database and KEGG. By querying GeneDB, we found that the genomic location from 872938 to 873820, named BCAL0802, was not assigned any function in the above two databases. A BLAST search of BCAL0802 against the UNIPROT database revealed a perfect match with IspE from other *B. cenocepacia* strains. Consequently, BCAL0802 is annotated as a 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase and this missing reaction was supplemented into the model *iKF1028*. This example exemplifies

how the reconstruction process can drive the reconciliation of isolated data from different biological databases.

BIOLOG substrate utilization assays have already been successfully used on the refinement of metabolic reconstructions [24]. It is an efficient approach for gap analysis and refinement of genome annotation. For example, in our study we can highlight the case for the substrate D-galactose, associated in BIOLOG assays with a growth phenotype. From that result we inferred that J2315 should contain a transport mechanism for D-galactose. By homology searches of MglA, MglB, and MglC, which are galactose-binding proteins conveying galactose into the cell, gene BCAL1431 (mglB), BCAL1432 (mglA), and BCAL1433 (mglC) were identified and they had been annotated as a putative sugar ABC transporter ATP-binding protein, a putative ribose ABC transport system, and a putative sugar transport system permease protein respectively. The ordering of mglB, mglA, and mglC is consistent with a) previous studies indicating that the *mgl* operon contains three genes and the genes are transcribed in the order of mglB, mglA, and mglC [66] and b) mglA and mglC being located downstream of mglB [67]. As a result, the annotations of BCAL1431-1433 were refined to account for the galactose transport. In total, 7 genes were reannotated based on BIOLOG assays.

Gene essentiality analysis

The term 'essential gene' means a gene for which knockout is lethal (*i.e.* no biomass yield) under certain conditions (*e.g.* glucose minimal medium) [68]. Identification of essential genes is helpful to understand the basic functions required for survival and it is an efficient way to discover novel targets for new antimicrobial therapies. Here in this study, *iKF1028* was used as a framework to predict computationally identified essential genes in *B. cenocepacia* J2315 on both M9 minimal medium and synthetic CF medium (SCFM). About 19% (192) and 15% (154) of the 1,028 metabolic genes included in *iKF1028* were predicted to be essential on M9 and SCFM media, respectively. There are more genes predicted as essentials on M9 than on SCFM, which indicates the influence of the living environment on the bacterium. 147 overlapping predictions were on both media. These essential genes are unequally located on the three chromosomes and most of the essential genes are located on chromosome 1 (Figure 4a). This result agrees with known features of the J2315 genome: chromosome 1 contains a higher proportion of coding sequence (CDS) involved in central metabolism and other house-keeping functions, whereas chromosomes 2 and 3 contain a greater proportion of CDS encoding accessory functions [13].

Table 4 Proposed annotation refinements

Gene Locus	Current Annotation (Burkholderia. com)	Proposed Reannotation	Protein name	Protein ID	Evidence
BCAL0691, BCAL2945	Putative cytidyltransferase, D-beta-D-heptose 7-phosphate kinase	Bifunctional protein RfaE domain II and I, respectively, sugar kinase/adenylyltransferase	RfaE	-	Modelling evidence, RfaE is necessary for biosynthesis of ADP-L-glycero-D-mannoheptose, a precursor for LPS inner core biosynthesis; BLAST search of RfaE from <i>P. aeruginosa</i> gave E values of 9E-35 and 1E-75, respectively
BCAL0780	Putative multiphosphoryl transfer protein	Glucose-specific enzyme IIA component of PTS	Crr	TC-4. A.1.1.1	BIOLOG assays indicated growth on glucose; BLAST search of Crr from <i>E.coli</i> gave an E value of 1E-28 and Identities of 40%
BCAL0781	Phosphotransferase system, Ilbc component	Glucose/N-acetyl glucosamine-specific IIC component	PtsG/ NagE	-	Evidence from BIOLOG assays; BLAST search of PtsG, NagE from <i>E.coli</i> gave E values of 3E-107, 7E-151 and Identities of 43%, 56%, respectively
BCAL0802	Gene locus is not assigned in <i>Burkholderia</i> Genome Database and KEGG	4-diphosphocytidyl-2-C-methyl-D-erythritol kinase	IspE	EC-2.7.1.148	Modelling evidence, IspE is necessary for biosynthesis of polyprenyl-PP, a precursor for ubiquinone biosynthesis; BLAST E value of 4E-172; assigned gene locus of BCAL0802 (from 872938 to 873820) in GeneDB database
BCAL1281	Hypothetical protein	Ornithine N-acetyltransferase	OlsB	EC-2.3.1.-	Physiological evidence from Weissenmayer <i>et al.</i> (2002); OlsB is required for the first step of ornithine-derived lipid biosynthesis; BLAST E value of 1E-29
BCAL1431, BCAL1432, BCAL1433	Putative sugar transport system	Galactose transport	MgIB, MgIA, MgIC	TC-3. A.1.2.3	BIOLOG assays indicated growth on galactose; and BLAST E values (< 2E-23)
BCAL1933, BCAL1934	Putative formyltransferase, NAD-dependent epimerase/dehydratase family protein	UDP-Ara4N formyltransferase, UDP-4'-keto-5'-carboxypentose decarboxylase	ArnA1, ArnA2	-	Evidence from Ortega <i>et al.</i> (2006). Unlike other bacteria in which <i>arnA</i> is a single gene encoding a bifunctional enzyme, two distinct genes were found in J2315 (<i>arnA1</i> and <i>arnA2</i>) and both are required for Ara4N biosynthesis
BCAL2388	Hypothetical protein	Glucose-1-phosphate adenylyltransferase	-	EC-2.7.7.27	Modelling evidence, a missing protein is required for glycogen biosynthesis; and BLAST search against UNIPROT database gave an E value of 9E-58
BCAL3280	Putative carbon-nitrogen hydrolase protein	Succinamic acid amidohydrolase	-	EC-3.5.1.3	BIOLOG assays indicated growth on succinamic acid; modelling showed a missing protein in this pathway; BLAST search against UNIPROT database gave an E value of 3E-46
BCAL3365	Putative gluconate permease	D-gluconate: H+ symporter	GntP	TC-2. A.8.1.3	BIOLOG assays indicated growth on D-Gluconic acid; modelling revealed a lack of transporter; BLAST E values of 4E-68
BCAM0469	Putative aldehyde dehydrogenase	Aldehyde dehydrogenase A, NAD-linked	AldA	EC-1.2.1.21	Modelling evidence: a gene is missing to synthesize glycolaldehyde which is required for biosynthesis of vitamin B6; BLAST E value of 2E-74
BCAM1404	Probable exported glycosyl hydrolase	Sucrose-6-phosphate hydrolase	ScrB	EC-3.2.1.26	BIOLOG assays indicated growth on sucrose; modelling showed missing protein along the pathway; gene locus identified from annotation as 93% similarity from <i>Staphylococcus aureus</i> and E value of 1E-33
BCAM2340, BCAM2338, BCAM2336	Putative (R)-3-hydroxydecanoyl-ACP: CoA transacylase, putative glycosyltransferase, putative sugar transferase	Rhamnopolysyltransferase chain A, Rhamnopolysyltransferase chain B, Rhamnopolysyltransferase 2	RhIA, RhIB, RhIC	-	Strong physiological evidence from Dubeau <i>et al.</i> (2009): <i>Burkholderia cepacia</i> complex (Bcc) can synthesize rhamnolipids; high homologous similarity of RhIA, RhIB, RhIC found in <i>B. cenocepacia</i> J2315 when compared with <i>P. aeruginosa</i> PAO1 and <i>B. thailandensis</i>
BCAM2496, BCAM2497, BCAM2498	Binding-protein-dependent transport system protein, ABC transporter ATP-binding protein, extracellular solute-binding protein	Thiamin transport via ATP-binding protein	ThiP, ThiQ, ThiB	TC-3. A.1.19.1	Genetic evidence: J2315 is unable to biosynthesize thiamin, which is an important cofactor to grow, by itself and could only obtain it from culture medium; BLAST search of ThiP, ThiQ, ThiB from <i>E.coli</i> got good result

Table 4 Proposed annotation refinements (Continued)

BCAM2723	Putative outer membrane porin protein	Pyroglutamate porin OpdO	OpdO	TC-1. B.25.1.7	Evidence from BIOLOG assays; BLAST search of OpdO from <i>P. aeruginosa</i> PAO1 versus the <i>B. cenocepacia</i> J2315 genome gave an E value of 4E-32
BCAM2795	Hypothetical protein	1,4-lactonase	-	EC- 3.1.1.25	BIOLOG assays indicated growth on galactose; modelling suggested a protein is missing in this pathway; BLAST search of 1,4-lactonase from <i>Xanthomonas campestris</i> gave an E value of 4E-55 and identities of 42%

To assess the predictive potential of the model, we compared the *in silico* essential genes predicted on SCFM with experimental essentiality data for *P. aeruginosa* PAO1 and *P. aeruginosa* PA14 [69,70] since there is no experimental gene essentiality data available for *B. cenocepacia*. As both *P. aeruginosa* and *B. cenocepacia* are CF pathogens, and *B. cenocepacia* was historically classified under the genus *Pseudomonas* [71], it is possible that partial similarity exists between them. SCFM was chosen due to its similarity to the nutritional composition of sputum from CF patients. The common set of the essential genes from two *P. aeruginosa* strains was chosen for comparison in order to reduce the effect of strain-dependent variation. Totally, there are 294 *in silico* essential metabolic and non-metabolic genes of *B. cenocepacia* J2315 with high similarity to the common set of *P. aeruginosa* by BLAST searches, of which 91 *in vivo* essential genes are present in *iKF1028*. Genes in the *in vivo* essential set but not in the *iKF1028* were assumed to be involved either in non-metabolic functions or in accessory functions of metabolism. A total of 55% (50) of the *in silico* predicted essential genes agreed with the *in vivo* essential genes based on gene homology with *P. aeruginosa* (Figure 4b, refer to Additional file 4 for detailed information about essential genes).

Based on gene essentiality analysis, the genome-scale metabolic model of *B. cenocepacia* was further refined. For example, BCAL0660 and BCAL3421, which were homologous genes encoding protein AccC according to their annotation, were originally both included in the model with the gene-protein-reaction (GPR) relationship of "BCAL0660 or BCAL3421". Through *in silico* gene deletion study, BCAL3421 is identified as non-essential, which is inconsistent with the *in vivo* essential gene results. Such discrepancy was subject to further analysis. AccA, AccB, AccC, and AccD were four subunits of Acetyl-CoA Carboxylase (ACC) catalyzing the first step of fatty acid biosynthesis [72]. The gene accB, of which the locus in J2315 is BCAL3420, is frequently adjacent to the gene accC and both genes are cotranscribed and form an operon together [73,74]. Furthermore, BCAL3420 and BCAL3421 shows greater than 2-fold expression for J2315 under CF conditions versus soil conditions, yet BCAL0660 shows an opposite result [75].


Taken together, BCAL0660 was excluded from model *iKF1028*. Further studies are necessary to validate the function of BCAL0660.

Identification of essential enzymes and potential drug targets

Essential enzyme/protein refers to a gene product (catalyzing the relevant reactions) for which individual deletion (*i.e.* imposing the fluxes through these reactions to zero) is lethal under certain conditions. Through FBA using *iKF1028*, we could obtain a collection of essential enzymes (protein), based on which 45 essential enzymes were identified as potential drug targets and supported by experimental evidences from literatures. There are 39 of them which were also predicted as drug targets for *P. aeruginosa* PAO1 [76]. All the 39 targets are nonhomologous to human protein sequences and thus could serve as potential candidate antibiotic drug targets for CF patients infected by both *B. cenocepacia* J2315 and *P. aeruginosa* PAO1. Among 39 targets, there are 9 targets, namely AccA, AccB, AccC, AccD, MurA, FolP, PhoA, RibE, and RibH, which have approved drugs in the DrugBank database [77].

The other 6 potential targets, namely ArnT, ArnB, ArnC, ArnA1, ArnA2, and Ugd are unique in *B. cenocepacia* J2315. ArnT, ArnB, ArnC, ArnA1, and ArnA2 are necessary proteins required for the synthesis of Ara4N, which is an additional moiety of LPS specially presented in *B. cenocepacia* J2315. Ara4N is essential for the viability of *B. cenocepacia* J2315 and significantly contributes to high resistance to antimicrobial peptides (AMPs) [54]. AMPs have been proposed as agents for treating CF infections [78,79]. It had also been demonstrated that arnC transposon mutant was survival-defective and attenuated in infected rats [48]. The UDP-glucose dehydrogenase (Ugd), which catalyzes the conversion of UDP-glucose to UDP-glucuronic acid and is the initial step in the synthesis of UDP-Ara4N, is also necessary for the viability of *B. cenocepacia* and its resistance to polymyxin B [80]. These targets are potentially useful for designing strategies against *B. cenocepacia* J2315. Further studies are necessary to test their applicability. An overview of the 45 proposed targets is given in Table 5.

a



b




Figure 4 Gene essentiality analysis. (a) Distribution of essential genes predicted on M9 and SCFM respectively; (b) Overlapping essential genes among *in silico* prediction on M9, SCFM, and essential genes with *in vivo* evidence from two *P. aeruginosa* strains: *P. aeruginosa* PAO1 and *P. aeruginosa* PA14.

Conclusions

In this study, we reconstructed the first manually curated genome-scale metabolic network of *B. cenocepacia* J2315, a Gram-negative pathogen for CF patients. An iterative reconstruction process led to the

establishment of the model, termed *iKF1028*, which captures the important metabolic capabilities and biosynthesis of key metabolic virulence factors. The model *iKF1028* shows its predictive potential when compared with BIOLOG assays. Model-driven analyses on gene

annotation refinement and identification of gene and enzyme essentiality analyses are helpful to understand the genome and discover promising novel drug targets. Through careful investigation, we proposed 45 enzymes that catalyze reactions predicted to be essential for growth with priority to be considered as drug targets. The model will keep being further validated and improved with experimentally determined biomass composition, large-scale gene deletion experimental data, proteome, and metabolome data, as they become available for *B. cenocepacia*. The model herein developed provides a valuable tool to explore the metabolic space of *B. cenocepacia*, to describe its metabolic wiring under a range of conditions, to pinpoint possible targets and to generate testable hypotheses. Taken together, our study underlined the value of the model *iKF1028* as a framework to systematically study the metabolic capabilities of *B. cenocepacia* and its metabolic virulence factors affecting the CF community.

Methods

Reconstruction of the metabolic network

The reconstruction process for *B. cenocepacia* J2315 is illustrated in Figure 5. The process followed the procedure described previously [81]. The reconstruction was carried out on ToBiN (Toolbox for Biochemical Networks, <http://www.lifewizz.com>), which was first mentioned in the paper [82]. ToBiN is a modular platform for metabolic modelling and the structural analysis of networks. It consists of a collection of open-source computational tools. Sets of reactions can be uploaded in the platform via a web interface, merged with already existing sets, and the resulting stoichiometric matrix is then processed by the server as a FBA problem. The linear solver that ToBiN used is the Clp (Coin-or linear programming), an open-source linear programming solver written in C++ and is part of the COIN-OR (Computational Infrastructure for Operations Research) project (<http://www.coin-or.org>). The platform works in a similar way as the COBRA toolbox with the main difference that, by being web-based, it permits users to adopt a more efficient and collaborative workflow.

An initial draft reconstruction was derived from the annotated genome of *Burkholderia cenocepacia* J2315 available at the *Burkholderia* Genome Database (<http://www.burkholderia.com>). To link annotated genes to proteins and proteins to reactions, biological databases such as KEGG, GeneDB, UniProt, BRENDA, Transport Classification Database (TCDB), and TransportDB were used [83-88]. Manual curations were performed to establish gene-protein-reaction (GPR) associations, which connect genetic data to reactions in the metabolic

network and allow for subsequent exploration of metabolic phenotypes using genetic perturbations.

After the initial reconstruction was generated, gaps in metabolic pathways necessary to produce biomass components and key virulence factors were filled by cautious literature mining, BIOLOG substrates utilization assays, and BLAST searches on homology and protein sequence similarity analyses [89,90]. The genome annotation was refined as consequence of the gap-filling and model extension process.

Flux Balance Analysis (FBA) was carried out throughout this study to explore the metabolic capabilities of *iKF1028* under various environments. In addition to minimal medium, synthetic cystic fibrosis medium (SCFM) representing the physical living environment during CF infection was simulated *in silico* to investigate the metabolic flux distribution in a CF-like condition.

Biomass composition

The biomass composition in the genome-scale metabolic model of *B. cenocepacia* J2315 was adapted by selecting the well-studied biomass composition of *E. coli* as a template [91], since there's no experimental data available about the biomass composition of *B. cenocepacia*. However, the amount of metabolic precursors to formulate the cellular component was specific to *B. cenocepacia* according to previous study [20]. Moreover, the relative fatty acid composition of the lipids required for growth was based on data specific to *B. cenocepacia* [63,64,92,93] and listed in Table 6. Further details are provided in the supplemental material [Additional file 5].

Flux balance analysis

Flux balance analysis (FBA) is an algorithm based on linear programming (LP) and on the assumption that the represented metabolic network is in steady-state (i.e. all the intracellular metabolite concentrations are constant). Being a LP problem, FBA also requires the selection of an objective function and of whether the value for that same function should be maximized or minimized. FBA is usually used to compute the optimal growth yield (the maximized objective function) based on the assumption that the evolutionary fitness of the organism depends on growth alone and, consequently, the implicit regulatory mechanism are organized to permit the theoretical maximal growth. If the system of equations (stoichiometric matrix which represents the metabolic network) is feasible, the algorithm generates an optimal flux distribution for that same network, taking into account the imposed thermodynamic constraints (reaction directionality) and limits on substrate uptake rates. The mathematical description is as follows:

Table 5 Proposed essential enzymes that can be candidate drug targets for *B. cenocepacia* J2315

Functional subsystem	EC No.	Protein	Enzyme name
Amino acid metabolism	EC-4.2.3.4	AroB	3-dehydroquinate synthase
	EC-4.2.3.5	AroC	Chorismate synthase
	EC-1.1.1.25	AroE	Shikimate dehydrogenase
	EC-1.3.1.26	DapB	Dihydrodipicolinate reductase
	EC-2.3.1.117	DapD	Tetrahydrodipicolinate succinylase
	EC-5.1.1.7	DapF	Diaminopimelate epimerase
Lipid synthesis	EC-2.7.2.4	LysC	Aspartate kinase
	EC-6.4.1.2	AccA*	Acetyl-CoA carboxylase carboxyltransferase subunit- α
	EC-6.4.1.2	AccB*	Acetyl-CoA carboxylase biotin carboxyl carrier protein subunit
	EC-6.4.1.2	AccC*	Acetyl-CoA carboxylase biotin carboxylase subunit
	EC-6.4.1.2	AccD*	Acetyl-CoA carboxylase subunit- β
Cell wall/LPS synthesis	EC-2.7.8.8	PssA	Phosphatidylserine synthase
	-	ArnA1 [#]	UDP-Ara4N formyltransferase
	-	ArnA2 [#]	UDP-4-keto-5-carboxypentose decarboxylase
	-	ArnB [#]	UDP-4-ketopentose aminotransferase
	-	ArnC [#]	Ara4N Und-P transferase
	-	ArnT [#]	Ara4N transferase
	EC-3.6.1.27	BacA	Undecaprenyl pyrophosphate phosphatase
	EC-2.5.1.55	KdsA	2-dehydro-3-deoxyphosphooctonate aldolase
	EC-2.7.7.38	KdsB	3-deoxy-manno-octulosonate cytidyltransferase
	EC-2.3.1.129	LpxA	UDP-N-acetylglucosamine acyltransferase
	EC-2.4.1.182	LpxB	Lipid-A-disaccharide synthase
	EC-3.5.1.-	LpxC	UDP-3-O-[3-hydroxymyristoyl]N-acetylglucosamine deacetylase
	EC-2.7.1.130	LpxK	Tetraacyldisaccharide 4'-kinase
	EC-2.5.1.7	MurA*	UDP-N-acetylglucosamine 1-carboxyvinyltransferase
	EC-1.1.1.158	MurB	UDP-N-acetylmuramate dehydrogenase
	EC-6.3.2.8	MurC	UDP-N-acetylmuramate-L-alanine ligase
	EC-6.3.2.9	MurD	UDP-N-acetylmuramoyl-L-alanyl-D-glutamate synthetase
	EC-6.3.2.13	MurE	UDP-N-acetylmuramoylalanyl-D-glutamate-2-, 6-diaminopimelate ligase
	EC-2.4.1.227	MurG	Undecaprenyldiphospho-muramoylpentapeptide- β -N-acetylglucosaminyltransferase
	EC-1.1.1.22	Udg [#]	UDP-glucose dehydrogenase
EC-2.4.1.-	WaaF	UDP-glucose:(heptosyl) LPS- α -1,3-glucosyltransferase	
EC-5.1.3.13	RmlC	dTDP-4-dehydrorhamnose 3,5-epimerase	
Vitamin and cofactor synthesis	EC-2.7.11.5	AceK	Bifunctional isocitrate dehydrogenase kinase/ phosphatase protein
	EC-4.1.2.25	FolB	Dihydroneopterin aldolase
	EC-2.5.1.15	FolP*	Dihydropteroate synthase
	EC-1.2.1.70	HemA	Glutamyl-tRNA reductase
	EC-2.1.2.11	PanB	3-methyl-2-oxobutanoate hydroxymethyltransferase
	EC-6.3.2.1	PanC	Pantoate- β -alanine ligase
	EC-1.1.1.169	PanE	2-dehydropantoate 2-reductase
	EC-3.1.3.1	PhoA*	Alkaline phosphatase
	EC-3.5.4.25	RibB	Bifunctional 3,4-dihydroxy-2-butanone 4-phosphate synthase
	EC-3.5.4.26	RibD	Riboflavin-specific deaminase/reductase
EC-2.5.1.9	RibE*	Riboflavin synthase subunit- α	
EC-2.5.1.9	RibH*	6,7-dimethyl-8-ribityllumazine synase	

[#] Essential enzymes unique for *B. cenocepacia* J2315 (others are shared between *B. cenocepacia* J2315 and *P. aeruginosa* PAO1).

* The proteins have had approved drugs from the DrugBank database.




Figure 5 The process for genome-scale metabolic reconstruction of *B. cenocepacia* J2315. The left side indicates resources used for reconstruction, and the right side indicates the reconstruction process. Initial reconstruction started from genome annotation and other biological databases. Gap-filling was a continuous step throughout the reconstruction by probing missing reactions in a pathway which causes *in silico* growth infeasible, and subsequently closing these gaps by referring to the biological databases, extensive literature mining, and comparison with BIOLOG substrate utilization assays [89,90]. This improved model was then extended by adding key metabolic virulence factors for *B. cenocepacia* from the literature. The process of model development and validation against experimental data was iteratively repeated until the genome-scale metabolic model was robust.

$$\begin{aligned} \max : & c^T \cdot v \\ \text{s.t.} : & \begin{cases} \sum_{j=1}^C S_{ij} \cdot v_j = 0 & \forall i \in \text{compounds} \\ v_{\min} \leq v_j \leq v_{\max} & \forall j \in \text{reactions} \end{cases} \end{aligned}$$

Where S is a stoichiometric matrix containing i rows representing metabolites and j columns representing reactions, v is a vector of all reaction fluxes, v_{\min} and v_{\max} are imposed lower and upper bounds on flux v_j

Table 6 Amino lipid composition of *B. cenocepacia* J2315

	Fatty acid	PE	PG	CLPN	OL
Saturated	16:0	+	+	+	ND
Unsaturated	16:1	+	+	+	ND
	18:1	+	+	+	+
Hydroxy	14:0 3OH	ND	ND	ND	+
	16:0 3OH	ND	ND	ND	+
Cyclopropane	17:0 CYC	+	+	+	ND
	19:0 CYC	+	+	+	ND

PE, phosphatidylethanolamine; PG, phosphatidylglycerol; CLPN, cardiolipin; OL, ornithine amide lipid; ND, not determined; plus symbol (+), fatty acid was detected in a significant amount

respectively, and c^T is a vector of coefficients for each reaction that is to be maximized.

In silico media composition

Two different living environments were simulated *in silico* for strain J2315: M9 minimal medium [94], which contains PO_4^{3-} , SO_4^{2-} , NH_4^+ , H^+ , Fe^{2+} , K^+ , Mg^{2+} , Na^+ , H_2O , and thiamine, with glucose or other BIOLOG substrates as sole carbon source; and synthetic CF sputum medium (SCFM) [95] representing the nutrient conditions inside a host-cell during CF infection. Details of the simulated SCFM composition are provided in the supplemental material [Additional file 6].

BIOLOG assay

To validate the model and estimate the metabolic capabilities of strain J2315, BIOLOG assay was performed by using various carbon sources for strain cultivation [16]. The BIOLOG assay was carried out in triplicates using Biolog GN2 MicroPlates (Biolog, Inc.), which can test the ability of a microorganism to oxidize a panel of 95 different carbon sources simultaneously. The procedure for using the MicroPlates was according to the manufacturer's specification. The strain J2315 was obtained from DSMZ GmbH (DSMZ 16553, equivalent to LMG 16656 as which strain J2315 has been deposited in the BCCM/LMG Bacteria Collection). The strain was cultured overnight in CASO agar plate. Then the bacteria were swabbed from the plate surface and suspended in GN/GP inoculating fluid (Biolog, Inc.) and 150 μl of the suspension was transferred to each well of the GN2 MicroPlate. The MicroPlates were incubated at 30°C for 48 hours and were read by a microplate reader at 24 and 48 hours and analyzed with the Biolog MicroLog3 4.20 software (Biolog, Inc.). A comparison between the BIOLOG results and *in silico* predictions is provided in the supplemental material. [Additional file 3]

Gene and enzyme essentiality

FBA can be used to interpret genetic modification, such as gene deletion and enzyme inhibition, and subsequently make comprehensive *in silico* predictions on gene and enzyme essentiality [96]. To assess the essentiality of a gene, its GPR is checked for a unique relation with the associated reaction(s). If the gene is necessary to the reaction, the reaction flux will be constrained to zero and a solution for the maximal growth yield is searched. The deleted gene is predicated to be essential if, as consequence of that added constraint, the value of the objective function (growth yield) changes to zero. The deletion of every gene accounted in the model was simulated for growth on minimal medium with glucose as sole carbon source, and on SCFM. Similarly, an enzyme is considered essential if, by constraining to

zero the flux on every associated reaction that has no alternative means of catalysis, the value for the growth yield changes to zero. The essentiality of every enzyme accounted in the model was analysed for growth on SCFM.

Additional material

Additional file 1: Reconstructed metabolic network model iKF1028

Additional file 2: Model iKF1028 in SBML format

Additional file 3: BIOLOG assays

Additional file 4: Gene essentiality comparison results

Additional file 5: Biomass detailed information

Additional file 6: Synthetic CF medium simulated *in silico*

Acknowledgements and Funding

We acknowledge funding from the European Union (Projects PROBACTYS: Grant No. 29104 and MICROME: No. 222886), the National Basic Research Program of China (973 Program) (Grant No. 2011CBA00802) from the Ministry of Science and Technology of the People's Republic of China, the Project for Young Scientists Fund, Institute of Psychology, Chinese Academy of Sciences (Grant No. O9CX115011), and Portuguese Fundação para a Ciência e Tecnologia (Project METAGUT; Grant No. ERA-PTG/SAU/0003/2008).

Author details

¹Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing 100101, China. ²College of Biological Sciences, China Agricultural University, Beijing 100193, China. ³Systems and Synthetic Biology Group, Helmholtz Center for Infection Research (HZI), Inhoffenstrasse 7, 38124 Braunschweig, Germany. ⁴Graduate University of Chinese Academy of Sciences, Beijing 100101, China. ⁵Lifewizz Lda, Rua Pero de Alenquer 123 7 E, 4150-616 Porto, Portugal. ⁶Systems and Synthetic Biology, Wageningen University, Dreijenplein 10, 6703 HB Wageningen, The Netherlands.

Authors' contributions

KCF, HSZ, SCY, SHC, and KLZ carried out the reconstruction of *Burkholderia cenocepacia* J2315. KCF designed the study and performed the analysis. KCF and CMCL arranged the BIOLOG substrate utilization analysis. JW and VMDS supervised the research. KCF, CMCL, VMDS, and JW drafted the manuscript. GP provided technical support for the reconstruction of *B. cenocepacia* J2315 in ToBiN. MG was involved in the early stage of the development of iKF1028 in ToBiN. All authors read and approved the final manuscript.

Received: 18 November 2010 Accepted: 25 May 2011

Published: 25 May 2011

References

1. Mahenthiralingam E, Baldwin A, Dowson CG: *Burkholderia cepacia* complex bacteria: opportunistic pathogens with important natural biology. *J Appl Microbiol* 2008, **104**:1539-1551.
2. Vanlaere E, Lipuma JJ, Baldwin A, Henry D, De Brandt E, Mahenthiralingam E, Speert D, Dowson C, Vandamme P: *Burkholderia latens* sp. nov., *Burkholderia diffusa* sp. nov., *Burkholderia arboris* sp. nov., *Burkholderia seminalis* sp. nov. and *Burkholderia metallica* sp. nov., novel species within the *Burkholderia cepacia* complex. *Int J Syst Evol Microbiol* 2008, **58**:1580-1590.
3. Vanlaere E, Baldwin A, Gevers D, Henry D, De Brandt E, Lipuma JJ, Mahenthiralingam E, Speert DP, Dowson C, Vandamme P: **Taxon K, a complex within the *Burkholderia cepacia* complex, comprises at least two novel species, *Burkholderia contaminans* sp. nov. and *Burkholderia lata* sp. nov.** *Int J Syst Evol Microbiol* 2009, **59**:102-111.
4. Parke JL, Gurian-Sherman D: Diversity of the *Burkholderia cepacia* complex and implications for risk assessment of biological control strains. *Annu Rev Phytopathol* 2001, **39**:225-258.
5. Mahenthiralingam E, Baldwin A, Vandamme P: *Burkholderia cepacia* complex infection in patients with cystic fibrosis. *J Med Microbiol* 2002, **51**:533-538.
6. Mahenthiralingam E, Urban TA, Goldberg JB: **The multifarious, multireplicon *Burkholderia cepacia* complex.** *Nat Rev Microbiol* 2005, **3**:144-156.
7. Mann T, Ben-David D, Zlotkin A, Shachar D, Keller N, Toren A, Nagler A, Smollan G, Barzilai A, Rahav G: **An outbreak of *Burkholderia cenocepacia* bacteremia in immunocompromised oncology patients.** *Infection* 2010.
8. Govan JR, Brown PH, Maddison J, Doherty CJ, Nelson JW, Dodd M, Greening AP, Webb AK: **Evidence for transmission of *Pseudomonas cepacia* by social contact in cystic fibrosis.** *Lancet* 1993, **342**:15-19.
9. Martin DW, Mohr CD: **Invasion and intracellular survival of *Burkholderia cepacia*.** *Infect Immun* 2000, **68**:24-29.
10. Vandamme P, Holmes B, Coenye T, Goris J, Mahenthiralingam E, Lipuma JJ, Govan JR: *Burkholderia cenocepacia* sp. nov.—a new twist to an old story. *Res Microbiol* 2003, **154**:91-96.
11. Drevinek P, Holden MT, Ge Z, Jones AM, Ketchell I, Gill RT, Mahenthiralingam E: **Gene expression changes linked to antimicrobial resistance, oxidative stress, iron depletion and retained motility are observed when *Burkholderia cenocepacia* grows in cystic fibrosis sputum.** *BMC Infect Dis* 2008, **8**:121.
12. Dubarry N, Du W, Lane D, Pasta F: **Improved electrotransformation and decreased antibiotic resistance of the cystic fibrosis pathogen *Burkholderia cenocepacia* strain J2315.** *Appl Environ Microbiol* 2010, **76**:1095-1102.
13. Holden MT, Seth-Smith HM, Crossman LC, Sebahia M, Bentley SD, Cerdeno-Tarraga AM, Thomson NR, Bason N, Quail MA, Sharp S, et al: **The genome of *Burkholderia cenocepacia* J2315, an epidemic pathogen of cystic fibrosis patients.** *J Bacteriol* 2009, **191**:261-277.
14. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI: **Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.** *Antimicrob Agents Chemother* 1998, **42**:2206-2214.
15. Loutet SA, Flanagan RS, Kooi C, Sokol PA, Valvano MA: **A complete lipopolysaccharide inner core oligosaccharide is required for resistance of *Burkholderia cenocepacia* to antimicrobial peptides and bacterial survival *in vivo*.** *J Bacteriol* 2006, **188**:2073-2080.
16. Miller JM, Rhoden DL: **Preliminary evaluation of Biolog, a carbon source utilization method for bacterial identification.** *J Clin Microbiol* 1991, **29**:1143-1147.
17. Reed JL, Vo TD, Schilling CH, Palsson BO: **An expanded genome-scale model of *Escherichia coli* K-12 (iJR904 GSM/GPR).** *Genome Biology* 2003, **4**:R45.
18. Lee DS, Burd H, Liu J, Almaas E, Wiest O, Barabasi AL, Oltvai ZN, Kapatral V: **Comparative genome-scale metabolic reconstruction and flux balance analysis of multiple *Staphylococcus aureus* genomes identify novel antimicrobial drug targets.** *J Bacteriol* 2009, **191**:4015-4024.
19. Becker SA, Palsson BO: **Genome-scale reconstruction of the metabolic network in *Staphylococcus aureus* N315: an initial draft to the two-dimensional annotation.** *BMC Microbiol* 2005, **5**:8.
20. Heinemann M, Kummel A, Ruinatscha R, Panke S: ***In silico* genome-scale reconstruction and validation of the *Staphylococcus aureus* metabolic network.** *Biotechnol Bioeng* 2005, **92**:850-864.
21. Kim HU, Kim TY, Lee SY: **Genome-scale metabolic network analysis and drug targeting of multi-drug resistant pathogen *Acinetobacter baumannii* AYE.** *Mol Biosyst* 2010, **6**:339-348.
22. Jamshidi N, Palsson BO: **Investigating the metabolic capabilities of *Mycobacterium tuberculosis* H37Rv using the *in silico* strain iNJ661 and proposing alternative drug targets.** *BMC Syst Biol* 2007, **1**:26.
23. Raghunathan A, Reed J, Shin S, Palsson B, Daeflter S: **Constraint-based analysis of metabolic capacity of *Salmonella typhimurium* during host-pathogen interaction.** *BMC Syst Biol* 2009, **3**:38.
24. Oberhardt MA, Puchalka J, Fryer KE, Martins dos Santos VA, Papin JA: **Genome-scale metabolic network analysis of the opportunistic pathogen *Pseudomonas aeruginosa* PAO1.** *J Bacteriol* 2008, **190**:2790-2803.
25. Eberl L: **Quorum sensing in the genus *Burkholderia*.** *Int J Med Microbiol* 2006, **296**:103-110.
26. Eberl L: **From a local dialect to a common language.** *Chem Biol* 2006, **13**:803-804.

27. Sokol PA, Malott RJ, Riedel K, Eberl L: **Communication systems in the genus *Burkholderia*: global regulators and targets for novel antipathogenic drugs.** *Future Microbiol* 2007, **2**:555-563.
28. Boon C, Deng Y, Wang LH, He Y, Xu JL, Fan Y, Pan SQ, Zhang LH: **A novel DSF-like signal from *Burkholderia cenocepacia* interferes with *Candida albicans* morphological transition.** *ISME J* 2008, **2**:27-36.
29. Deng Y, Boon C, Eberl L, Zhang LH: **Differential modulation of *Burkholderia cenocepacia* virulence and energy metabolism by the quorum-sensing signal BDSF and its synthase.** *J Bacteriol* 2009, **191**:7270-7278.
30. Ryan RP, McCarthy Y, Watt SA, Niehaus K, Dow JM: **Intraspecies signaling involving the diffusible signal factor BDSF (cis-2-dodecanoic acid) influences virulence in *Burkholderia cenocepacia*.** *J Bacteriol* 2009, **191**:5013-5019.
31. Sokol PA, Darling P, Woods DE, Mahenthalingam E, Kooi C: **Role of ornibactin biosynthesis in the virulence of *Burkholderia cepacia*: characterization of *pvdA*, the gene encoding L-ornithine N(5)-oxygenase.** *Infect Immun* 1999, **67**:4443-4455.
32. Farmer KL, Thomas MS: **Isolation and characterization of *Burkholderia cenocepacia* mutants deficient in pyochelin production: pyochelin biosynthesis is sensitive to sulfur availability.** *J Bacteriol* 2004, **186**:270-277.
33. Visser MB, Majumdar S, Hani E, Sokol PA: **Importance of the ornibactin and pyochelin siderophore transport systems in *Burkholderia cenocepacia* lung infections.** *Infect Immun* 2004, **72**:2850-2857.
34. Sajjan US, Sun L, Goldstein R, Forstner JF: **Cable (*cbl*) type II pili of cystic fibrosis-associated *Burkholderia (Pseudomonas) cepacia*: nucleotide sequence of the *cblA* major subunit pilin gene and novel morphology of the assembled appendage fibers.** *J Bacteriol* 1995, **177**:1030-1038.
35. Sajjan U, Ackerley C, Forstner J: **Interaction of *cblA*/adhesin-positive *Burkholderia cepacia* with squamous epithelium.** *Cell Microbiol* 2002, **4**:73-86.
36. Sajjan U, Liu L, Lu A, Spilker T, Forstner J, LiPuma JJ: **Lack of cable pili expression by *cblA*-containing *Burkholderia cepacia* complex.** *Microbiology* 2002, **148**:3477-3484.
37. Tomich M, Herfst CA, Golden JW, Mohr CD: **Role of flagella in host cell invasion by *Burkholderia cepacia*.** *Infect Immun* 2002, **70**:1799-1806.
38. Urban TA, Griffith A, Torok AM, Smolkin ME, Burns JL, Goldberg JB: **Contribution of *Burkholderia cenocepacia* flagella to infectivity and inflammation.** *Infect Immun* 2004, **72**:5126-5134.
39. Hutchison ML, Poxton IR, Govan JR: ***Burkholderia cepacia* produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes.** *Infect Immun* 1998, **66**:2033-2039.
40. Kooi C, Corbett CR, Sokol PA: **Functional analysis of the *Burkholderia cenocepacia* *ZmpA* metalloprotease.** *J Bacteriol* 2005, **187**:4421-4429.
41. Kooi C, Subsin B, Chen R, Pohorelic B, Sokol PA: ***Burkholderia cenocepacia* *ZmpB* is a broad-specificity zinc metalloprotease involved in virulence.** *Infect Immun* 2006, **74**:4083-4093.
42. Kooi C, Sokol PA: ***Burkholderia cenocepacia* zinc metalloproteases influence resistance to antimicrobial peptides.** *Microbiology* 2009, **155**:2818-2825.
43. Korbsrisate S, Tomaras AP, Damnin S, Ckumdee J, Srinon V, Lengwehasatit I, Vasil ML, Suparak S: **Characterization of two distinct phospholipase C enzymes from *Burkholderia pseudomallei*.** *Microbiology* 2007, **153**:1907-1915.
44. Tomich M, Griffith A, Herfst CA, Burns JL, Mohr CD: **Attenuated virulence of a *Burkholderia cepacia* type III secretion mutant in a murine model of infection.** *Infect Immun* 2003, **71**:1405-1415.
45. Engledow AS, Medrano EG, Mahenthalingam E, LiPuma JJ, Gonzalez CF: **Involvement of a plasmid-encoded type IV secretion system in the plant tissue watersoaking phenotype of *Burkholderia cenocepacia*.** *J Bacteriol* 2004, **186**:6015-6024.
46. Markey KM, Glendinning KJ, Morgan JA, Hart CA, Winstanley C: ***Caenorhabditis elegans* killing assay as an infection model to study the role of type III secretion in *Burkholderia cenocepacia*.** *J Med Microbiol* 2006, **55**:967-969.
47. Ortega X, Hunt TA, Loutet S, Vinion-Dubiel AD, Datta A, Choudhury B, Goldberg JB, Carlson R, Valvano MA: **Reconstitution of O-specific lipopolysaccharide expression in *Burkholderia cenocepacia* strain J2315, which is associated with transmissible infections in patients with cystic fibrosis.** *J Bacteriol* 2005, **187**:1324-1333.
48. Hunt TA, Kooi C, Sokol PA, Valvano MA: **Identification of *Burkholderia cenocepacia* genes required for bacterial survival in vivo.** *Infect Immun* 2004, **72**:4010-4022.
49. De Soyza A, Silipo A, Lanzetta R, Govan JR, Molinaro A: **Chemical and biological features of *Burkholderia cepacia* complex lipopolysaccharides.** *Innate Immun* 2008, **14**:127-144.
50. Parsons YN, Banasko R, Detsika MG, Duangsonk K, Rainbow L, Hart CA, Winstanley C: **Suppression-subtractive hybridisation reveals variations in gene distribution amongst the *Burkholderia cepacia* complex, including the presence in some strains of a genomic island containing putative polysaccharide production genes.** *Arch Microbiol* 2003, **179**:214-223.
51. Silipo A, Molinaro A, Ierano T, De Soyza A, Sturiale L, Garozzo D, Aldridge C, Corris PA, Khan CM, Lanzetta R, Parrilli M: **The complete structure and pro-inflammatory activity of the lipooligosaccharide of the highly epidemic and virulent gram-negative bacterium *Burkholderia cenocepacia* ET-12 (strain J2315).** *Chemistry* 2007, **13**:3501-3511.
52. Ortega X, Silipo A, Saldias MS, Bates CC, Molinaro A, Valvano MA: **Biosynthesis and structure of the *Burkholderia cenocepacia* K56-2 lipopolysaccharide core oligosaccharide: truncation of the core oligosaccharide leads to increased binding and sensitivity to polymyxin B.** *J Biol Chem* 2009, **284**:21738-21751.
53. Vinion-Dubiel AD, Goldberg JB: **Lipopolysaccharide of *Burkholderia cepacia* complex.** *J Endotoxin Res* 2003, **9**:201-213.
54. Ortega XP, Cardona ST, Brown AR, Loutet SA, Flannagan RS, Campopiano DJ, Govan JR, Valvano MA: **A putative gene cluster for aminoarabinose biosynthesis is essential for *Burkholderia cenocepacia* viability.** *J Bacteriol* 2007, **189**:3639-3644.
55. Chung HS, Raetz CRH: **Identification and characterization of a 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) oxidase; KdoO.** *The FASEB Journal* 2010.
56. Kenna DT, Barcus VA, Langley RJ, Vandamme P, Govan JR: **Lack of correlation between O-serotype, bacteriophage susceptibility and genomovar status in the *Burkholderia cepacia* complex.** *FEMS Immunol Med Microbiol* 2003, **35**:87-92.
57. Malott RJ, Baldwin A, Mahenthalingam E, Sokol PA: **Characterization of the *cilIR* quorum-sensing system in *Burkholderia cenocepacia*.** *Infect Immun* 2005, **73**:4982-4992.
58. Williams P, Winzer K, Chan WC, Camara M: **Look who's talking: communication and quorum sensing in the bacterial world.** *Philos Trans R Soc Lond B Biol Sci* 2007, **362**:1119-1134.
59. Baldwin A, Sokol PA, Parkhill J, Mahenthalingam E: **The *Burkholderia cepacia* epidemic strain marker is part of a novel genomic island encoding both virulence and metabolism-associated genes in *Burkholderia cenocepacia*.** *Infect Immun* 2004, **72**:1537-1547.
60. Diggle SP, Mattheijs S, Wright VJ, Fletcher MP, Chhabra SR, Lamont IL, Kong X, Hider RC, Cornelis P, Camara M, Williams P: **The *Pseudomonas aeruginosa* 4-quinolone signal molecules HHQ and PQS play multifunctional roles in quorum sensing and iron entrapment.** *Chem Biol* 2007, **14**:87-96.
61. Dubeau D, Deziel E, Woods DE, Lepine F: ***Burkholderia thailandensis* harbors two identical *rhl* gene clusters responsible for the biosynthesis of rhamnolipids.** *BMC Microbiol* 2009, **9**:263.
62. Coenye T, Vandamme P, Govan JR, LiPuma JJ: **Taxonomy and identification of the *Burkholderia cepacia* complex.** *J Clin Microbiol* 2001, **39**:3427-3436.
63. Wilkinson S, Pitt T: ***Burkholderia (Pseudomonas) cepacia*: Surface chemistry and typing methods.** *REV MED MICROBIOL* 1995, **6**:1-9.
64. Taylor CJ, Anderson AJ, Wilkinson SG: **Phenotypic variation of lipid composition in *Burkholderia cepacia*: a response to increased growth temperature is a greater content of 2-hydroxy acids in phosphatidylethanolamine and ornithine amide lipid.** *Microbiology* 1998, **144**(Pt 7):1737-1745.
65. Gao JL, Weissenmayer B, Taylor AM, Thomas-Oates J, Lopez-Lara IM, Geiger O: **Identification of a gene required for the formation of lyso-ornithine lipid, an intermediate in the biosynthesis of ornithine-containing lipids.** *Mol Microbiol* 2004, **53**:1757-1770.
66. Harayama S, Bollinger J, Iino T, Hazelbauer GL: **Characterization of the *mgl* operon of *Escherichia coli* by transposon mutagenesis and molecular cloning.** *J Bacteriol* 1983, **153**:408-415.
67. Stamm LV, Young NR, Frye JG, Hardham JM: **Identification and sequences of the *Treponema pallidum* *mglA* and *mglC* genes.** *DNA Seq* 1996, **6**:293-298.

68. Koonin EV: **Comparative genomics, minimal gene-sets and the last universal common ancestor.** *Nat Rev Microbiol* 2003, **1**:127-136.
69. Jacobs MA, Alwood A, Thaipisuttikul I, Spencer D, Haugen E, Ernst S, Will O, Kaul R, Raymond C, Levy R, et al: **Comprehensive transposon mutant library of *Pseudomonas aeruginosa*.** *Proc Natl Acad Sci USA* 2003, **100**:14339-14344.
70. Liberati NT, Urbach JM, Miyata S, Lee DG, Drenkard E, Wu G, Villanueva J, Wei T, Ausubel FM: **An ordered, nonredundant library of *Pseudomonas aeruginosa* strain PA14 transposon insertion mutants.** *Proc Natl Acad Sci USA* 2006, **103**:2833-2838.
71. Yabuuchi E, Kosako Y, Oyaizu H, Yano I, Hotta H, Hashimoto Y, Ezaki T, Arakawa M: **Proposal of *Burkholderia* gen. nov. and transfer of seven species of the genus *Pseudomonas* homology group II to the new genus, with the type species *Burkholderia cepacia* (Palleroni and Holmes 1981) comb. nov.** *Microbiol Immunol* 1992, **36**:1251-1275.
72. Cronan JE Jr, Waldrop GL: **Multi-subunit acetyl-CoA carboxylases.** *Prog Lipid Res* 2002, **41**:407-435.
73. Li SJ, Cronan JE Jr: **Growth rate regulation of *Escherichia coli* acetyl coenzyme A carboxylase, which catalyzes the first committed step of lipid biosynthesis.** *J Bacteriol* 1993, **175**:332-340.
74. Abdel-Hamid AM, Cronan JE: **Coordinate expression of the acetyl coenzyme A carboxylase genes, accB and accC, is necessary for normal regulation of biotin synthesis in *Escherichia coli*.** *J Bacteriol* 2007, **189**:369-376.
75. Yoder-Himes DR, Konstantinidis KT, Tiedje JM: **Identification of potential therapeutic targets for *Burkholderia cenocepacia* by comparative transcriptomics.** *PLoS One* 2010, **5**:e8724.
76. Perumal D, Samal A, Sakharkar KR, Sakharkar MK: **Targeting multiple targets in *Pseudomonas aeruginosa* PAO1 using flux balance analysis of a reconstructed genome-scale metabolic network.** *J Drug Target* 2010.
77. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M: **DrugBank: a knowledgebase for drugs, drug actions and drug targets.** *Nucleic Acids Res* 2008, **36**:D901-906.
78. Zhang L, Parente J, Harris SM, Woods DE, Hancock RE, Falla TJ: **Antimicrobial peptide therapeutics for cystic fibrosis.** *Antimicrob Agents Chemother* 2005, **49**:2921-2927.
79. Mookherjee N, Hancock RE: **Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections.** *Cell Mol Life Sci* 2007, **64**:922-933.
80. Loutet SA, Bartholdson SJ, Govan JR, Campopiano DJ, Valvano MA: **Contributions of two UDP-glucose dehydrogenases to viability and polymyxin B resistance of *Burkholderia cenocepacia*.** *Microbiology* 2009, **155**:2029-2039.
81. Edwards JS, Covert M, Palsson BO: **Metabolic modelling of microbes: the flux-balance approach.** *Environmental Microbiology* 2002, **4**:133-140.
82. Diez MS, Lam CM, Leprince A, dos Santos VA: **(Re-)construction, characterization and modeling of systems for synthetic biology.** *Biotechnol J* 2009, **4**:1382-1391.
83. Hertz-Fowler C, Peacock CS, Wood V, Aslett M, Kerhornou A, Mooney P, Tivey A, Berriman M, Hall N, Rutherford K, et al: **GeneDB: a resource for prokaryotic and eukaryotic organisms.** *Nucleic Acids Res* 2004, **32**:D339-343.
84. Schomburg I, Chang A, Ebeling C, Gremse M, Heldt C, Huhn G, Schomburg D: **BRENDA, the enzyme database: updates and major new developments.** *Nucleic Acids Res* 2004, **32**:D431-433.
85. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, Katayama T, Araki M, Hirakawa M: **From genomics to chemical genomics: new developments in KEGG.** *Nucleic Acids Res* 2006, **34**:D354-357.
86. Ren Q, Chen K, Paulsen IT: **TransportDB: a comprehensive database resource for cytoplasmic membrane transport systems and outer membrane channels.** *Nucleic Acids Res* 2007, **35**:D274-279.
87. **The universal protein resource (UniProt).** *Nucleic Acids Res* 2008, **36**:D190-195.
88. Saier MH Jr, Tran CV, Barabote RD: **TCDB: the Transporter Classification Database for membrane transport protein analyses and information.** *Nucleic Acids Res* 2006, **34**:D181-186.
89. Orth JD, Palsson BO: **Systematizing the generation of missing metabolic knowledge.** *Biotechnol Bioeng* 2010, **107**:403-412.
90. Reed JL, Patel TR, Chen KH, Joyce AR, Applebee MK, Herring CD, Bui OT, Knight EM, Fong SS, Palsson BO: **Systems approach to refining genome annotation.** *Proc Natl Acad Sci USA* 2006, **103**:17480-17484.
91. Feist AM, Henry CS, Reed JL, Krummenacker M, Joyce AR, Karp PD, Broadbelt LJ, Hatzimanikatis V, Palsson BO: **A genome-scale metabolic reconstruction for *Escherichia coli* K-12 MG1655 that accounts for 1260 ORFs and thermodynamic information.** *Molecular Systems Biology* 2007, **3**.
92. Krejci E, Kroppenstedt RM: **Differentiation of Species Combined into the *Burkholderia cepacia* Complex and Related Taxa on the Basis of Their Fatty Acid Patterns.** *Journal of Clinical Microbiology* 2006, **44**.
93. Sousa SA, Ramos CG, Almeida F, Meirinhos-Soares L, Wopperer J, Schwager S, Eberl L, Leitao JH: ***Burkholderia cenocepacia* J2315 acyl carrier protein: a potential target for antimicrobials' development?** *Microb Pathog* 2008, **45**:331-336.
94. Miller JH: *Experiments in molecular genetics* Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory; 1972.
95. Palmer KL, Aye LM, Whiteley M: **Nutritional cues control *Pseudomonas aeruginosa* multicellular behavior in cystic fibrosis sputum.** *J Bacteriol* 2007, **189**:8079-8087.
96. Joyce AR, Reed JL, White A, Edwards R, Osterman A, Baba T, Mori H, Lesley SA, Palsson BO, Agarwalla S: **Experimental and computational assessment of conditionally essential genes in *Escherichia coli*.** *J Bacteriol* 2006, **188**:8259-8271.

doi:10.1186/1752-0509-5-83

Cite this article as: Fang et al.: Exploring the metabolic network of the epidemic pathogen *Burkholderia cenocepacia* J2315 via genome-scale reconstruction. *BMC Systems Biology* 2011 **5**:83.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

